Medtronic MDT Cardiovascular — Selling, general, and administrative expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Medtronic in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Medtronic’s 10-K, filed June 18, 2026, on SEC EDGAR. View the filing →
Ask your AI about Medtronic's cardiovascular — selling, general, and administrative expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Medtronic's cardiovascular — selling, general, and administrative expense?
- Medtronic (MDT) reported cardiovascular — selling, general, and administrative expense of $1.19B in Q1 2026.
- How has Medtronic's cardiovascular — selling, general, and administrative expense changed year-over-year?
- Medtronic's cardiovascular — selling, general, and administrative expense increased by 17.4% year-over-year, from $1.01B to $1.19B.
- What is the long-term trend for Medtronic's cardiovascular — selling, general, and administrative expense?
- Over 3 years (2023 to 2026), Medtronic's cardiovascular — selling, general, and administrative expense has grown at a 19.4% compound annual growth rate (CAGR), from $2.65B to $4.52B.
- What does cardiovascular — selling, general, and administrative expense mean?
- The total cost of selling, marketing, and administrative support for the cardiovascular business.
- How do you interpret cardiovascular — selling, general, and administrative expense?
- Lower expenses relative to sales indicate high operational leverage, while rising expenses may signal aggressive market expansion or inefficiency.
- How does cardiovascular — selling, general, and administrative expense compare across companies?
- Comparable to SG&A expenses in the cardiovascular divisions of global medical device competitors.